Blog

16 February 2026

Rezpegaldesleukin Demonstrates Long-Term Efficacy in Atopic Dermatitis Trial

Discover the long-term efficacy of rezpegaldesleukin in treating moderate-to-severe atopic dermatitis, as revealed in the groundbreaking REZOLVE-AD trial results.
Read more
Rezpegaldesleukin Demonstrates Long-Term Efficacy in Atopic Dermatitis Trial
New Phase 3 Study Confirms Apremilast’s Efficacy for Genital Psoriasis

New Phase 3 Study Confirms Apremilast’s Efficacy for Genital Psoriasis

Discover how a new Phase 3 study confirms apremilast's efficacy for genital psoriasis, offering hope for those suffering from this...
15 02 2026
Read more
FDA Reviews Biofrontera’s Photodynamic Therapy for Superficial BCC

FDA Reviews Biofrontera’s Photodynamic Therapy for Superficial BCC

FDA reviews Biofrontera's Ameluz for treating superficial basal cell carcinoma (sBCC). Discover the potential expansion of this innovative photodynamic therapy.
14 02 2026
Read more
Rapid Advances in Litifilimab: Insights from LILAC to AMETHYST in CLE

Rapid Advances in Litifilimab: Insights from LILAC to AMETHYST in CLE

Explore rapid advances in litifilimab for cutaneous lupus erythematosus (CLE) from the LILAC study to the AMETHYST program and its...
13 02 2026
Read more
Red Light PDT: Establishing New Standards for Treating Superficial BCC

Red Light PDT: Establishing New Standards for Treating Superficial BCC

Discover how red light PDT with 10% ALA gel is setting new standards in treating superficial BCC, backed by robust...
12 02 2026
Read more
FDA Revamps iPLEDGE REMS: Key Changes for Pregnancy Testing and Prescriptions

FDA Revamps iPLEDGE REMS: Key Changes for Pregnancy Testing and Prescriptions

Discover the FDA's key changes to the iPLEDGE REMS for isotretinoin. Learn how new pregnancy testing and prescription guidelines will...
11 02 2026
Read more
New Phase 3 Results Elevate Oral TYK2 Inhibitors in Psoriasis Treatment

New Phase 3 Results Elevate Oral TYK2 Inhibitors in Psoriasis Treatment

Discover how new Phase 3 results for oral TYK2 inhibitors, like zasocitinib, are transforming psoriasis treatment and challenging traditional biologic...
10 02 2026
Read more
Revolutionizing Non-Surgical Treatment for Superficial BCC with Red Light PDT

Revolutionizing Non-Surgical Treatment for Superficial BCC with Red Light PDT

Discover how red light photodynamic therapy (PDT) is revolutionizing non-surgical treatment for superficial BCC, offering new hope for patients. Read...
10 02 2026
Read more
Innovative Treatment Strategies for Inflammatory Skin Diseases Explored

Innovative Treatment Strategies for Inflammatory Skin Diseases Explored

Discover innovative treatment strategies for inflammatory skin diseases like atopic dermatitis, psoriasis, and hidradenitis suppurativa in our latest expert interview.
9 02 2026
Read more